Lifeboat Foundation

Medcalf: Because you’re moving away from the economics of scale to closer to the clinic, the batches are smaller and some of the traditional paradigms for quality assurance, such as proof of sterility, are harder to arrange. Thus, you need to have a manufacturing system that includes quality assurance within the system itself.

Automation is often presented as a way to remove the single largest source of infective risk, i.e. the human operator. For example, the self-sterilizing reusable units being developed at the University of Osaka under Professor Masahiro Kino-oka allow small-scale production with a high degree of confidence in the aseptic management of the environment.

Another challenge is defining a product that has variable characteristics. The main reason for decentralizing is to allow customization to a patient, which means you need to have a hierarchy of levels of specification. For example, with bioprinting, which also produces a customized product, you need to define bulk properties, but you also need to set constraints around how it’s anchored or implanted into the patient.

Bioprinting is widely applicable to develop tissue engineering scaffolds and form tissue models in the lab. Materials scientists use this method to construct complex 3D structures based on different polymers and hydrogels; however, relatively low resolution and long fabrication times can result in limited procedures for cell-based applications.

In a new report now available in Nature Asia Materials, Byungjun Lee and a team of scientists in mechanical engineering at Seoul National University, Seoul, Korea, presented a 3D hybrid-micromesh assisted bioprinting method (Hy-MAP) to combine digital light projection, 3D printed micromesh scaffold sutures, together with sequential hydrogel patterning. The new method of bioprinting offered rapid cell co-culture via several methods including injection, dipping and draining. The work can promote the construction of mesoscale complex 3D hydrogel structures across 2D microfluidic channels to 3D channel networks.

Lee et al. established the design rules for Hy-MAP printing via analytical and experimental investigations. The new method can provide an alternative technique to develop mesoscale implantable tissue engineering constructs for organ-on-a-chip applications.

A research team from Utrecht University has successfully fabricated working livers using a newly developed ultrafast volumetric 3D bioprinting method.

By means of visible light tomography, the volumetric bioprinting method enabled the successful printing of miniature stem cell units by making the cells “transparent”, which meant they retained their resolution and ability to perform biological processes.

Printed in less than 20 seconds, the liver units were able to perform key toxin elimination processes mimicking those that natural livers perform in our bodies, and could open new opportunities for regenerative medicine and personalized drug testing.

NASA’s band-aid tool uses cells to heal in space.

NASA is testing a prototype device called Bioprint FirstAid Handheld Bioprinter — or Bioprint FirstAid — to heal injuries sustained in space.

Researchers from the University of Birmingham and the University of Huddersfield, UK, have developed a new 3D bioprinting technique that can be used to treat chronic wounds.

Named Suspended Layer Additive Manufacturing (SLAM), the approach enables the printing of a novel biomaterial that accurately simulates the structure of mammalian skin.

In fact, according to the researchers, the biomaterial is the first of its kind to simulate all three of the major layers found in skin – the hypodermis, the dermis, and the epidermis – making it a unique tri-layered skin equivalent. Early experiments suggest that the 3D bioprinted skin can be placed at the site of a wound to induce healing, reducing scar tissue in the process.

About the Bioprint FirstAid Handheld Bioprinter capabilities.

Astronauts on the International Space Station (ISS) are testing 3D bioprinted bandages made of their own cells that could be used to better heal flesh wounds in space.

The German Space Agency (DLR) is leading the experiment which was launched to the ISS at the end of December 2021 on SpaceX’s 24th commercial resupply mission. The payload contained the BioPrint FirstAid Handheld Bioprinter, which is designed to hold cells from astronauts within a bioink that can be used to apply bandages to wounds when needed.

Continue reading “Astronauts test 3D bioprinted skin bandages in space” »

Bio-Printing Complex Human Tissues & Organs — Dr. Anthony Atala, MD — Director, Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Wake Forest University.

Dr. Anthony Atala, MD, (https://school.wakehealth.edu/Faculty/A/Anthony-Atala) is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology.

Continue reading “Dr Anthony Atala, MD — Director, Wake Forest Inst for Regenerative Medicine — Printing Human Tissues” »

A major obstacle to widespread study and clinical use of 3D tissues is their short shelf-life, which may be anywhere from a just few hours to a few days. As in the case of an organ transplant, a bioprinted tissue must be transported rapidly to the location where it is needed, or it will not be viable. In the journal Matter on December 21^st, researchers at Brigham and Women’s Hospital and Harvard Medical School describe their work combining 3D bioprinting with cryopreservative techniques to create tissues which can be preserved in a freezer at-196°C and thawed within minutes for immediate use.

“For conventional bioprinting, there is basically no shelf life. It’s really just print, and then use, in most cases,” says lead author Y. Shrike Zhang (@shrikezhang), a biomedical engineer at Brigham and Women’s Hospital. “With cryobioprinting, you can print and store in the frozen state for basically as long as you want.”

Continue reading “3D-bioprinted tissues can now be stored in the freezer until needed” »

The 24thSpaceX cargo resupply services mission, targeted to launch in late December from NASA’s Kennedy Space Center in Florida, carries scientific research and technology demonstrations to the International Space Station. The experiments aboard include studies of bioprinting, crystallization of monoclonal antibodies, changes in immune function, plant gene expression changes, laundering clothes in space, processing alloys, and student citizen science projects.